These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22302016)

  • 21. The androgen receptor cytosine-adenine-guanine repeat length contributes to the development of epithelial ovarian cancer.
    Meng X; Lu P; Chu Z; Fan Q
    Oncotarget; 2016 Jan; 7(2):2105-12. PubMed ID: 26556855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort.
    Ose J; Schock H; Tjønneland A; Hansen L; Overvad K; Dossus L; Clavel-Chapelon F; Baglietto L; Boeing H; Trichopolou A; Benetou V; Lagiou P; Masala G; Tagliabue G; Tumino R; Sacerdote C; Mattiello A; Bueno-de-Mesquita HB; Peeters PH; Onland-Moret NC; Weiderpass E; Gram IT; Sánchez S; Obon-Santacana M; Sànchez-Pérez MJ; Larrañaga N; Castaño JM; Ardanaz E; Brändstedt J; Lundin E; Idahl A; Travis RC; Khaw KT; Rinaldi S; Romieu I; Merritt MA; Gunter MJ; Riboli E; Kaaks R; Fortner RT
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):951-61. PubMed ID: 25855626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
    Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
    Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations in expression pattern of splicing factors in epithelial ovarian cancer and its clinical impact.
    Iborra S; Hirschfeld M; Jaeger M; Zur Hausen A; Braicu I; Sehouli J; Gitsch G; Stickeler E
    Int J Gynecol Cancer; 2013 Jul; 23(6):990-6. PubMed ID: 23748175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction value of XRCC 1 gene polymorphism on the survival of ovarian cancer treated by adjuvant chemotherapy.
    Miao J; Zhang X; Tang QL; Wang XY; Kai L
    Asian Pac J Cancer Prev; 2012; 13(10):5007-10. PubMed ID: 23244100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension.
    Sakurai M; Satoh T; Matsumoto K; Michikami H; Nakamura Y; Nakao S; Ochi H; Onuki M; Minaguchi T; Yoshikawa H
    Int J Gynecol Cancer; 2015 May; 25(4):593-8. PubMed ID: 25756402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
    Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
    Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
    Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
    Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
    Shaboodien R; Diamantis N; Blagden S; Gabra H; Agarwal R
    Int J Gynecol Cancer; 2013 Mar; 23(3):481-7. PubMed ID: 23392404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
    Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
    Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
    Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
    Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.
    Sanada S; Futami K; Terada A; Yonemoto K; Ogasawara S; Akiba J; Yasumoto M; Sumi A; Ushijima K; Kamura T; Furuichi Y; Yano H
    PLoS One; 2013; 8(8):e72820. PubMed ID: 23951333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
    Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
    Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
    Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
    Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
    Liblab S; Vusuratana A; Areepium N
    Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?
    Reitsma W; de Bock GH; Oosterwijk JC; ten Hoor KA; Hollema H; Mourits MJ
    Int J Gynecol Cancer; 2012 May; 22(4):579-85. PubMed ID: 22274543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
    Brandt S; Samartzis EP; Zimmermann AK; Fink D; Moch H; Noske A; Dedes KJ
    BMC Cancer; 2017 Jan; 17(1):44. PubMed ID: 28073364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.